Title Page
Abstract
Contents
Introduction 11
Methods 14
Results 25
Discussion 79
References 86
국문 초록 93
Table 1. The number of measurable tumors according to the round of in vivo passing 38
Table 2. List of genes for RT-qPCR 57
Table 3. Clinical characteristics of human ATC 69
Fig 1. In vivo passaging of TBP3743 cells. 31
Fig 2. Sequencing of BrafV600E mutation. 33
Fig 3. Comparisons of thyroid differentiation markers between original and adapted TBP3743 cells. 34
Fig 4. Comparisons of cell migration potentials between original and adapted TBP3743 cells. 35
Fig 5. Comparisons of epithelial-mesenchymal markers and oncogenic signalings between original and adapted TBP3743 cells. 36
Fig 6. Establishment of orthotopic tumor model using TBP3743-B6 cells. 42
Fig 7. Molecular characteristics of orthotopic tumors from the adapted TBP3743 cells. 47
Fig 8. Molecular characteristics of the immune microenvironment in adapted TBP3743 cell-derived orthotopic tumors. 54
Fig 9. Comparisons of tumorigenicity between original and adapted TBP3743 cells in T cell-deficient mice. 56
Fig 10. Immune cell profiling of the orthotopic tumor microenvironment. 64
Fig 11. Comparisons of immune cell profiling in tumors between original/129, adapted/B6, and SC6/B6 models. 66
Fig 12. Comparisons of MHC class I expressions in original and dapted TBP3743 cells. 68
Fig 13. Effects of BRAFV⁶⁰⁰E inhibitor on adapted TBP3743-B6 cells.[이미지참조] 74
Fig 14. Combination therapeutic effects of BRAF inhibitor, anti-CD47 and PD-L1 in adapted/B6 tumor model. 78